Lantern Pharma - LTRN Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.77
▲ +0.17 (4.72%)

This chart shows the closing price for LTRN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lantern Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LTRN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LTRN

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Lantern Pharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.77.

This chart shows the closing price for LTRN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 polled investment analysts is to hold stock in Lantern Pharma. This rating has held steady since March 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/15/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/14/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/12/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/6/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/6/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/25/2024HC WainwrightReiterated RatingNeutral
5/18/2023HC WainwrightReiterated RatingNeutral
3/21/2023EF Hutton Acquisition Co. IReiterated RatingBuy$11.00
2/15/2023EF Hutton Acquisition Co. IReiterated RatingBuy$11.00
11/1/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$11.00
3/22/2022Colliers SecuritiesReiterated RatingBuy
3/11/2022HC WainwrightBoost TargetBuy$34.00 ➝ $36.00
11/2/2021HC WainwrightBoost TargetBuy$32.00 ➝ $34.00
10/7/2021HC WainwrightInitiated CoverageBuy$32.00
7/30/2021Colliers SecuritiesReiterated RatingBuy$29.00
7/21/2021Colliers SecuritiesReiterated RatingBuy$29.00
8/18/2020ThinkEquityReiterated RatingBuy ➝ Market Perform$25.00
8/18/2020Colliers SecuritiesReiterated RatingBuy ➝ Market Perform$24.00
8/10/2020ThinkEquityInitiated CoverageBuy
7/28/2020Colliers SecuritiesInitiated CoverageBuy$24.00
(Data available from 10/6/2019 forward)

News Sentiment Rating

0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/10/2024
  • 3 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
4/9/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/9/2024
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/8/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/8/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/7/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/6/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/6/2024

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Lantern Pharma logo
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Read More

Today's Range

Now: $3.77
Low: $3.55
High: $3.84

50 Day Range

MA: $3.97
Low: $3.35
High: $4.65

52 Week Range

Now: $3.77
Low: $2.38
High: $11.99

Volume

23,757 shs

Average Volume

146,617 shs

Market Capitalization

$40.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56

Frequently Asked Questions

What sell-side analysts currently cover shares of Lantern Pharma?

The following Wall Street sell-side analysts have issued reports on Lantern Pharma in the last year: HC Wainwright.
View the latest analyst ratings for LTRN.

What is the current price target for Lantern Pharma?

0 Wall Street analysts have set twelve-month price targets for Lantern Pharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Lantern Pharma in the next year.
View the latest price targets for LTRN.

What is the current consensus analyst rating for Lantern Pharma?

Lantern Pharma currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in LTRN, but not buy more shares or sell existing shares.
View the latest ratings for LTRN.

What other companies compete with Lantern Pharma?

How do I contact Lantern Pharma's investor relations team?

Lantern Pharma's physical mailing address is 1920 MCKINNEY AVENUE 7TH FLOOR, DALLAS TX, 75201. The company's listed phone number is 972-277-1136 and its investor relations email address is [email protected]. The official website for Lantern Pharma is www.lanternpharma.com. Learn More about contacing Lantern Pharma investor relations.